Personalizing Financial Incentives (Log2LoseAI)
Log2LoseAI: Reinforcement Learning to Create a Framework for Personalizing Financial Incentives
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Corrine Voils, PhD
- Phone Number: 801-585-6667
- Email: corrine.voils@hsc.utah.edu
Study Contact Backup
- Name: Fiona Robertson
- Email: fiona.robertson@hsc.utah.edu
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84108
- University of Utah
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Willing to attend virtual baseline and follow-up data collection visits
- At least 18 years of age
- Verified obesity as defined as a BMI ≥30 kg/m2
- Agree to attend 13 biweekly group classes (virtual) delivered by a registered dietitian
- Agree to review study materials between classes
- Regular access to an unshared smart phone
- Reliable access to internet
- Able to speak and read English
- Desire to lose weight
- Able to connect to a video conference call using a smartphone, tablet or computer with a webcam and microphone
- Ability to download and use Fitbit app daily
- Have or be willing to create a Gmail address
- Physical ability to stand on a scale without support
Exclusion Criteria:
- Weight loss of at least 10lbs in the month prior to screening
- Weight > 380lbs
- Currently enrolled or enrolled in the previous month in a clinical, research, or community program focusing on lifestyle change that could affect weight
- New user of weight loss medication
- Pregnant, lactating or planning on becoming pregnant during the study
- History of bariatric procedure or planning to have bariatric procedure in the study timeframe
- Residing in a nursing home, skilled nursing facility or assisted living facility
- Impaired hearing
- Significant dementia, drug or alcohol abuse, or unstable psychiatric illness (e.g., schizophrenia, psychosis)
- Current treatment for cancer or being treated for cancer (besides basal cell carcinoma or squamous cell) in the last 6 months
- Use of insulin, sulfonylureas, or meglitinides due to increased risk for hypoglycemia
- Diuretic medication doses higher than hydrochlorothiazide or chlorthalidone 25 mg daily, furosemide 40 mg daily, torsemide 20 mg daily, bumetanide 1 mg daily, or any use of metolazone; use of potassium-sparing diuretics is acceptable
- Unstable heart disease in the 6 months prior to screening
- Chronic kidney disease at stage 4 or higher
- Exertional chest pain
- Pain, fainting, or other conditions that prohibit mild/moderate exercise
- History of ascites requiring paracentesis
- Inducing vomiting to prevent weight gain or counteract the effects of eating an average of 1 time per week or more in the past 3 months*
- Not suitable for study participation due to other reasons at the discretion of the investigators
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Personalized incentives
Participants may receive financial incentives for weight loss if their performance suggests they respond to financial incentives.
|
Every week, a reinforcement learning algorithm will process data on weight loss, calorie logging, and incentives earned to predict that their weight loss is positively influenced by incentives.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Screening-to-enrollment ratio
Time Frame: Week 0
|
number of potential participants screened for the study/ number of participants who provide a baseline weight for the intervention
|
Week 0
|
|
Retention for outcomes
Time Frame: 25 weeks
|
number of participants who provide a weight at 25 weeks/number of participants who provide a baseline weight for the intervention
|
25 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adherence to calorie logging
Time Frame: 24 weeks
|
Proportion of weeks participants achieve adequate calorie logging (5 days per week)
|
24 weeks
|
|
Adherence to self-weighing
Time Frame: 24 weeks
|
Proportion of weeks participants weigh at least twice per week on a study-provided cellular scale
|
24 weeks
|
|
Body weight
Time Frame: baseline to 25 weeks
|
Changes in body weight from baseline to week 25, measured by study-provided cellular scales
|
baseline to 25 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 00188990
- R34HL170205 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.